As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None
This article was originally published in The Pink Sheet Daily
Executive Summary
A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.
You may also be interested in...
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia
Statins represent a high standard of care for managing high blood cholesterol, bolstered by a strong evidence base, but new targets like PCSK9 and CETP are nevertheless stealing the spotlight nowadays. Whether new drugs, if they make it to market, will be used beyond narrow, targeted population segments is uncertain and will depend on results from large-scale outcomes studies showing significant efficacy and, importantly, reassurance of a solid safety profile.